We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
European drug regulatory bodies and GlaxoSmithKline have quickly rallied their rebuttals to a BMJ report that questioned the safety profile of GSK’s now-unavailable pandemic flu vaccine Pandemrix...
It isn’t a scene one would expect after the world battled a severe flu season. But in China, supply of flu vaccines this season has come down, thanks to reduced offering from Sanofi Pasteur..
Seqirus has big plans for its cell-based flu vaccine franchise, and after a scale-up to reach 20 million doses this year, the company still needs more capacity.